An intricate Web: chemokine receptors, HIV-1 and hematopoiesis

Stem Cells
B LeeR W Doms

Abstract

Cellular infection by the human immunodeficiency virus type 1 (HIV-1) requires interaction of the viral envelope protein with CD4 and at least one additional cell surface molecule, termed a "cofactor" or "coreceptor." Recent discoveries have determined that macrophage-tropic strains of HIV-1 which are largely responsible for sexual transmission require the beta-chemokine receptor CCR5 in addition to CD4, while the T cell tropic viruses that emerge later after infection use the alpha-chemokine receptor CXCR4. Thus, both CD4 and the appropriate chemokine receptor must be expressed on the cell surface in order for HIV-1 to enter the cell and establish an infection. The in vivo importance of CCR5 for HIV-1 is demonstrated by the finding that individuals homozygous for a 32 bp deletion (delta 32) in the CCR5 gene that renders them effectively CCR5-negative are highly resistant to virus infection. In this review, the structure-function correlates of the chemokine receptors that serve as major coreceptors for HIV-1 and simian immunodeficiency virus entry will be reviewed. Since certain chemokines have been implicated as stem cell inhibitory factors, the biological consequences of chemokine receptor expression as it relates to HIV-1-as...Continue Reading

References

Jan 1, 1989·AIDS·J A McKeating, R L Willey
Jul 11, 1986·Science·S GartnerM Popovic
Dec 1, 1994·Blood Reviews·A W HarbolC N Abboud
Mar 1, 1995·Baillière's Clinical Haematology·B R Davis, G Zauli
Mar 1, 1995·Blood Reviews·M H EllisJ E Groopman
Nov 1, 1993·AIDS·J A Levy
Feb 17, 1997·The Journal of Experimental Medicine·R I ConnorN R Landau
Mar 4, 1997·Proceedings of the National Academy of Sciences of the United States of America·D Unutmaz, D R Littman

❮ Previous
Next ❯

Citations

Dec 12, 2001·European Journal of Haematology·T RozmyslowiczM Z Ratajczak
Sep 14, 2011·Immunology and Cell Biology·Mohamed El Gazzar, Charles E McCall
Sep 25, 2002·The European Journal of Neuroscience·Mauro VairanoPierluigi Navarra
Mar 20, 2002·The Journal of Experimental Medicine·Oliver T KepplerMark A Goldsmith
Feb 6, 2004·Current Opinion in Pediatrics·Amy E Geddis, Kenneth Kaushansky
Mar 13, 2003·Proceedings of the National Academy of Sciences of the United States of America·Huilin QiCatherine M Verfaillie
Jun 17, 2004·British Journal of Haematology·Shai Izraeli
Feb 28, 2003·Clinical and Experimental Immunology·D GibelliniG Zauli
Mar 31, 2005·Analytical Biochemistry·Iva NavratilovaDavid G Myszka
Aug 8, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·Jamie J BernardRichard P Phipps
Jan 5, 2005·Nature Reviews. Cancer·Johann K Hitzler, Alvin Zipursky
Mar 15, 2006·Development Genes and Evolution·Benjamin M HoganGraham J Lieschke
Nov 25, 2003·Hematology·Paul A VolberdingAlexandra M Levine
Dec 21, 2018·Cell Communication and Signaling : CCS·Sara Ortiz-RiveroCarmen Guerrero
Oct 22, 2009·Experimental Lung Research·Bin LiuHan-min Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.